In the current study, we aimed to compare the level of genetic damages measured as micronucleus (MN), nucleoplasmic bridge (NPB), and nuclear bud formation (NBUD) in congenital hearing loss patients (n = 17) and control group (n = 24). The cytokinesis-blocked micronucleus assay (CBMN) was applied to the blood samples to measure the frequency of the markers in both groups. The frequencies of MN of hearing loss patients were found to be consistently significantly higher than those obtained for the control group (p < 0.0001). Similarly, we found significantly higher frequency of NPB in patients was obtained for the patient group (p < 0.0001). Finally, the frequencies of NBUD in patients is significantly higher than the level measured in the control group (p < 0.0001). Furthermore, the age-adjusted MNL, BNMN, NPB, and NBUD frequencies in the patients were significantly higher than those obtained in the control group. We observed that the frequency of MN in patients was positively correlated with NBUD frequency which may indicate a common mechanism for these biomarkers in the patient group. We found, for the first time, that there were statistically significant higher levels of MN, NPB, and NBUD in sensorineural hearing loss patients. Since the markers we evaluated were linked with crucial diseases, our findings might suggest that sensorineural hearing loss patients are susceptible to several crucial diseases, especially cancer. Furthermore, the results demonstrated the significance of the MN, NPB, and NBUD level and thus provides a potential marker for the diagnosis of congenital hearing loss patients.

在目前的研究中，我们旨在比较先天性听力损失患者（n = 17）和对照组（n = 24)。将胞质分裂阻断微核试验 (CBMN) 应用于血样以测量两组中标记物的频率。发现听力损失患者的 MN 频率始终显着高于对照组 ( p < 0.0001)。同样，我们发现患者组的 NPB 频率显着更高（p < 0.0001）。最后，患者 NBUD 的频率显着高于对照组测量的水平（p< 0.0001)。此外，患者年龄调整后的 MNL、BNMN、NPB 和 NBUD 频率显着高于对照组。我们观察到患者中 MN 的频率与 NBUD 频率呈正相关，这可能表明患者组中这些生物标志物的共同机制。我们首次发现，感音神经性听力损失患者的 MN、NPB 和 NBUD 水平在统计学上显着升高。由于我们评估的标志物与关键疾病有关，我们的研究结果可能表明感音神经性听力损失患者易患几种关键疾病，尤其是癌症。此外，结果证明了 MN、NPB、